insights_auto
Why is 2359 down 2,19%?
Dive Deeperchevron_right
2359:HKG
WuXi AppTec Ord Shs H
HK$196,20
arrow_downward
-2,19%(-4,40) 1D
16 ຕ.ລ., 16 ໂມງ 8 ນາທີ 14 ວິນາທີ GMT+8 · HKD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 2359...
Open
HK$203,80
High
HK$209,00
Low
HK$185,00
Mkt. cap
544,52 ຕື້
Avg. vol.
3,91 ລ້ານ
Volume
10,16 ລ້ານ
Dividend
1,22%
Quarterly dividend
HK$0,60
Ex-dividend date
4 ກ.ຍ. 2026
P/E ratio
23,98
52-wk high
HK$219,20
52-wk low
HK$96,70
EPS
HK$8,18
No. of employees
36 ພັນ
Open
HK$203,80
High
HK$209,00
Low
HK$185,00
Mkt. cap
544,52 ຕື້
Avg. vol.
3,91 ລ້ານ
Volume
10,16 ລ້ານ
Dividend
1,22%
Quarterly dividend
HK$0,60
Ex-dividend date
4 ກ.ຍ. 2026
P/E ratio
23,98
52-wk high
HK$219,20
52-wk low
HK$96,70
EPS
HK$8,18
No. of employees
36 ພັນ
News stories
From web sources and news partners
ad-hoc-news.de
·
4 ຊົ່ວໂມງກ່ອນ
WuXi AppTec earns EcoVadis gold: what it means for WuXi AppTec stock
Profile
WuXi AppTec Co., Ltd. is a Chinese provider of contract research, development, and manufacturing, services for the pharmaceutical and life-sciences industry, headquartered in Shanghai, China. The company operates research and manufacturing facilities in Asia, North America, and Europe.
Founded in 2000 by chemist Ge Li as WuXi PharmaTech, the company expanded through acquisitions and re‑listings in 2018 after a 2015 take‑private. It produces a large part of the ingredients used in treatments for illnesses including leukemia, lymphoma, HIV, and obesity. As of 2025, the company reported around 39,000 employees and 6,000 customers. Its clients have included Jiangsu Hengrui, GlaxoSmithKline, AstraZeneca and Pfizer. Wikipedia
About WuXi AppTec Ord Shs H
CEOSteve Yang | Ge Li
Employees35,6 ພັນ
Founded1 ທ.ວ. 2000
Headquarters-
SectorHealth care
Websitewuxiapptec.com.cn